News from other Hematologic Malignancies

Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.

Meletios A. Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.

Conclusions: The IR combination demonstrated superior efficacy to R, producing significant improvements in PFS for all WM patients regardless of prognostic or genotypic factors with a predictable toxicity profile. IR should be considered a standard therapeutic option for patients with WM. Clinical trial information: NCT02165397

ABSTRACT 8003

SEE ALSO PUBLICATION IN THE NEJM